Metastatic prostate cancer occurs when cancer cells spread beyond the prostate gland to other parts of the body. The bones and lymph nodes are common sites, although the disease may also reach the liver, lungs, or other organs.
Although metastatic prostate cancer is not usually considered curable, modern treatments can often control it for a significant period. They may slow disease progression, reduce symptoms, and help patients live longer.
Enzalutamide is an oral targeted hormonal therapy that has become an important treatment option for certain patients with metastatic prostate cancer. It works by interfering with androgen receptor signalling, a pathway that prostate cancer cells commonly use to survive and multiply.
| Feature | Details | Why It Matters |
|---|---|---|
| Medicine type | Androgen receptor inhibitor | Identifies enzalutamide as targeted hormonal therapy rather than traditional chemotherapy |
| Main use | Treatment of selected forms of advanced prostate cancer | Helps control prostate cancer that is metastatic, castration-sensitive, or castration-resistant in appropriate patients |
| Administration | Oral capsules or tablets | Allows the medicine to be taken by mouth according to the prescribed schedule |
| Common prescribed dose | 160 mg once daily, subject to medical direction | Consistent daily dosing helps maintain the intended level of treatment |
| Food requirement | Generally taken with or without food | Provides flexibility when planning the daily dose |
| Main action | Blocks androgen receptor signalling in prostate cancer cells | Reduces signals that can encourage prostate cancer cells to survive and multiply |
| Treatment duration | Continued according to response, tolerability, and specialist advice | Treatment length varies according to disease control, side effects, and individual health |
| Routine steroid required | Not generally required solely with enzalutamide | Distinguishes it from certain hormonal treatments that are routinely given with corticosteroids |
| Medical supervision | Treatment must be prescribed and monitored by a specialist | Regular monitoring helps evaluate treatment response, interactions, and potential adverse effects |
Androgens promote prostate cancer growth by attaching to androgen receptors inside cancer cells. The activated receptors can then move into the nucleus and interact with DNA, switching on genes that support cancer-cell survival and multiplication.
Enzalutamide disrupts this process at several stages.
It may help by:
In simple terms, enzalutamide makes it more difficult for prostate cancer cells to use androgen hormones as a source of growth stimulation.
Enzalutamide has expanded treatment possibilities for patients at different stages of advanced prostate cancer. It can be taken orally and does not usually require the routine corticosteroid treatment needed with certain other hormonal medicines.
Clinical studies have shown that enzalutamide can improve important outcomes in appropriately selected patients. Depending on the treatment setting, these outcomes may include delayed disease progression, improved radiographic progression-free survival, and longer overall survival.
Potential benefits may include:
These benefits are not guaranteed for every patient. Response depends on the cancer’s biology, previous treatments, disease burden, general health, and other clinical factors.
Enzalutamide begins blocking androgen receptor signalling soon after treatment starts. However, patients may not notice an immediate improvement in their symptoms. The time it takes to produce a measurable response can vary depending on the stage of prostate cancer, previous treatments, overall health, and how the cancer responds.
A reduction in prostate-specific antigen (PSA) may be one of the earliest signs that enzalutamide is working. Changes in tumours or metastatic areas can take longer to confirm through imaging scans.
There is no fixed response timeline for every patient. The healthcare team will regularly evaluate:
Patients should continue taking enzalutamide exactly as prescribed, even if they do not notice an immediate difference. Treatment should not be stopped or changed based on PSA results or symptoms without consulting the treating specialist.
An oncologist may consider enzalutamide for patients with:
The treatment decision should not be based on PSA results alone. Doctors also consider symptoms, imaging findings, testosterone levels, previous therapies, medical history, and the expected benefits and risks of available treatments.
Enzalutamide is taken by mouth. The prescribing information commonly recommends a total dose of 160 mg once daily, but only the treating doctor should determine the correct dose and schedule for an individual patient.
It may generally be taken with or without food. The medicine should be taken at approximately the same time each day to maintain consistent drug levels.
Depending on the supplied formulation, patients should swallow the capsules or tablets whole. They should not chew, dissolve, crush, open, or divide them unless their healthcare provider or the approved product instructions specifically advise otherwise.
When enzalutamide is used for metastatic castration-sensitive or castration-resistant prostate cancer, medical or surgical castration is generally continued. Patients who have not had surgical removal of the testicles usually remain on a gonadotropin-releasing hormone treatment unless their specialist advises otherwise.
Instructions for a missed dose should follow the approved patient information supplied with the medicine.
In general, if a patient forgets a dose, it may be taken when remembered on the same day. If the entire day has passed, the missed dose is usually skipped, and the regular dose is resumed the following day.
Two doses should not be taken together to replace a missed dose. Patients who frequently forget their medicine should speak with their treatment team about reminders or other adherence support.
Regular monitoring helps doctors understand whether treatment is working and identify adverse effects before they become serious.
| Test or assessment | What it evaluates | How it may guide care |
|---|---|---|
| PSA blood test | Changes in prostate cancer activity | A falling or stable PSA may suggest benefit, while a rising level may require further assessment |
| Testosterone test | Whether androgen suppression remains adequate | Confirms that testosterone continues to be maintained at the intended low level |
| Complete blood count | Red blood cells, white blood cells, and platelets | Helps identify anaemia or other blood-count abnormalities |
| Liver and kidney tests | Organ function and general treatment safety | May influence treatment planning and the use of other medicines |
| Blood pressure measurement | New or worsening hypertension | May lead to closer monitoring or blood-pressure treatment |
| Imaging scans | Changes in tumours, lymph nodes, bones, or organs | Shows whether metastatic disease is stable, shrinking, or progressing |
| Symptom review | Pain, fatigue, mobility, appetite, and urinary symptoms | Helps evaluate both treatment benefit and quality of life |
| Medication review | Potential prescription, non-prescription, and herbal interactions | Helps prevent reduced effectiveness or increased toxicity |
| Fall and fracture assessment | Balance, muscle strength, and bone health | May identify the need for fall-prevention or bone-protection measures |
| Neurological assessment | Seizure risk, confusion, weakness, headaches, or visual symptoms | Helps identify rare but potentially serious complications |
A change in PSA does not always provide a complete picture. A rising PSA may prompt further investigation, but doctors generally consider laboratory results, imaging, symptoms, and overall health together.
Not every patient experiences the same adverse effects. Some effects remain mild and manageable, while others may require supportive treatment, dose interruption, or a change in therapy.
Commonly reported effects include:
Fatigue can be particularly important because it may affect mobility, independence, concentration, and daily routines. Patients should report persistent or worsening tiredness rather than assuming it is an unavoidable part of cancer treatment.
Enzalutamide can affect liver enzymes that process many other medicines. As a result, it may reduce the effectiveness of some treatments or alter their concentrations in the body. Other medicines may also change the amount of enzalutamide in the bloodstream.
Potentially important categories include:
This list is not complete. Patients should provide their oncology team with an updated list of every prescription medicine, over-the-counter product, vitamin, supplement, and herbal remedy they use.
No medicine should be started, stopped, or replaced without checking for interactions.
Before prescribing enzalutamide, the healthcare team should be informed about:
Patients should also discuss how treatment may affect driving, employment, exercise, sexual health, fertility, and everyday activities.
Enzalutamide is used to treat prostate cancer, but exposure during pregnancy may harm an unborn child.
A male patient with a partner who is pregnant should generally use a condom during treatment and for the period stated in the approved prescribing information after the last dose. If the partner could become pregnant, effective contraception may also be required during treatment and for the recommended period afterwards.
Patients who may want children in the future should discuss fertility preservation before beginning treatment.
The exact contraception period can differ by product label and country, so patients must follow their oncologist’s advice and local prescribing information.
Treatment response is assessed over time rather than through a single test.
Signs of treatment benefit may include:
A falling PSA can be encouraging, but it does not always prove that every tumour site is responding. Conversely, one unusual PSA result does not automatically mean that treatment has failed.
Prostate cancer cells may eventually adapt to androgen receptor inhibition. This is known as treatment resistance.
If there are signs of progression, the healthcare team may:
The best next step depends on previous therapies, the location and extent of metastases, genetic test results, symptoms, organ function, and patient preferences.
Patients should not continue, discontinue, or combine cancer medicines without specialist direction.
| Treatment feature | Enzalutamide | Chemotherapy |
|---|---|---|
| Treatment type | Androgen receptor inhibitor | Cytotoxic systemic treatment |
| Main action | Blocks androgen receptor signalling | Damages or disrupts rapidly dividing cells |
| Administration | Taken orally | Usually given through a vein, depending on the medicine |
| Steroid requirement | Routine steroid use is not generally required solely for enzalutamide | Steroids may form part of some chemotherapy regimens |
| Common concerns | Fatigue, hypertension, falls, fractures, interactions, and rare neurological effects | Infection risk, low blood counts, nausea, hair loss, and nerve problems, depending on the drug |
| Monitoring | PSA, imaging, blood pressure, symptoms, and safety assessments | Blood counts, organ function, symptoms, imaging, and treatment response |
| Role in metastatic disease | May be used in both castration-sensitive and castration-resistant settings | May be used in selected hormone-sensitive or castration-resistant settings |
One treatment is not universally better than the other. Some patients may receive both at different stages, while selected patients may be offered more intensive combination therapy from the beginning.
Medical disclaimer: This content is for general educational purposes and does not replace professional medical advice, diagnosis, or treatment. Enzalutamide is a prescription medicine and should only be used under the supervision of a qualified oncology specialist. Dose, duration, monitoring, and approved uses may differ by patient and country.
This article was written fresh for your request. While I have not copied it from another website or reused a prepared article, no one can reliably guarantee that every phrase is unlike all content ever published online.
